Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | protoporphyrinogen oxidase | 0.0366 | 1 | 0.5 |
Echinococcus granulosus | protoporphyrinogen oxidase | 0.0318 | 0.8347 | 0.5 |
Schistosoma mansoni | Protoporphyrinogen oxidase chloroplast/mitochondrial precursor | 0.0366 | 1 | 1 |
Echinococcus multilocularis | protoporphyrinogen oxidase | 0.0366 | 1 | 0.5 |
Trypanosoma brucei | RNA helicase, putative | 0.0258 | 0.6288 | 1 |
Mycobacterium tuberculosis | Probable protoporphyrinogen oxidase HemY (protoporphyrinogen-IX oxidase) (protoporphyrinogenase) (PPO) | 0.0318 | 0.8347 | 0.5 |
Mycobacterium leprae | PROBABLE PROTOPORPHYRINOGEN OXIDASE HEMY (PROTOPORPHYRINOGEN-IX OXIDASE) (PROTOPORPHYRINOGENASE) (PPO) | 0.0366 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 107 nM | Inhibitory concentration of morphine was measured in muscle of the guinea pig ileum | ChEMBL. | 3009817 |
IC50 (functional) | = 206 nM | Inhibitory concentration of compound was measured in muscle of the guinea pig ileum | ChEMBL. | 3009817 |
IC50 ratio (functional) | = 3.1 | Ratio of IC50 of ethylketazocine (EK) in the presence of compound to IC50 of ethylketazocine in the absence of compound | ChEMBL. | 3009817 |
Relative potency (functional) | = 5.2 | The agonist potency of compound was determined relative to control morphine IC50 | ChEMBL. | 3009817 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.